Molecular Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Molecular Diagnostics Market Report is Segmented by Technology (In Situ Hybridization, Chips and Microarrays, Mass Spectrometry (MS), Sequencing, PCR, and Other Technologies), Application (Infectious Disease, Oncology, Pharmacogenomics, Microbiology, and Genetic Disease Screening, Human Leukocyte Antigen Typing, and Blood Screening), Product (Instruments, Reagents, and Other Products), End User (Hospitals, Laboratories, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Industry Research Report Offers the Value (USD) for all the Above Segments.

Molecular Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Molecular Diagnostics Market Size

Molecular Diagnostics Market (2024 - 2029)
Study Period 2019 - 2030
Market Size (2025) USD 14.21 Billion
Market Size (2030) USD 22.08 Billion
CAGR (2025 - 2030) 9.22 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Molecular Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Molecular Diagnostics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Molecular Diagnostics Market Analysis

The Molecular Diagnostics Market size is estimated at USD 14.21 billion in 2025, and is expected to reach USD 22.08 billion by 2030, at a CAGR of 9.22% during the forecast period (2025-2030).

The global molecular diagnostics market is undergoing rapid expansion, driven by several macroeconomic trends and technological advancements. These molecular diagnostics market trends include the increasing incidence of infectious diseases and cancers, growing focus on personalized medicine, and continual improvements in diagnostic techniques. The analysis of specific drivers aligns with these overarching megatrends, leading to significant market growth.

Large Outbreaks of Bacterial and Viral Epidemics: The rising prevalence of infectious diseases has created a substantial demand within the infectious disease molecular diagnostics market. These diagnostic tools are among the most precise methods for identifying and characterizing microorganisms, offering accurate and rapid detection of infection levels. Molecular diagnostics have played a critical role in managing outbreaks of diseases such as COVID-19, Zika, MERS, and Influenza, among others. Their capacity to quickly determine organism strains and antibiotic resistance has drastically improved patient outcomes by reducing delays in effective treatment selection.

Increasing Demand for Point-of-Care Diagnostics: The demand within the POC molecular diagnostics market has surged, revolutionizing healthcare by enabling rapid disease detection. These diagnostics deliver faster results than conventional methods, improving diagnosis and monitoring outcomes. POC tests are available for pathogens like Tuberculosis and Influenza, with the COVID-19 pandemic accelerating market adoption. The cost-efficiency and precision of POC diagnostics, especially in primary care, make them a valuable tool for managing chronic conditions such as Type 2 Diabetes, monitored through glycated hemoglobin A1c testing.

Technological Advancements and Pharmacogenomics Growth: The molecular diagnostics field continues to evolve, driven by rapid technological advancements. Key technologies include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), and next-generation biosensors. The increased demand for faster diagnostics has spurred significant R&D in the field, with key molecular diagnostics companies developing advanced molecular diagnostic methods. Pharmacogenomics, central to personalized medicine, has benefited from substantial investments by governments and private entities. This has led to significant adoption of molecular diagnostics for analyzing genetic data quickly, bolstering the molecular diagnostics market growth as personalized medicine becomes more prevalent.

In conclusion, the molecular diagnostics industry is set for continued growth, propelled by the increasing incidence of infectious diseases, heightened demand for POC diagnostics, and constant technological evolution. The integration of these factors is facilitating the adoption of more precise, efficient, and personalized diagnostic solutions across diverse medical fields, expanding the molecular diagnostic testing market.

Molecular Diagnostics Industry Overview

Global Leaders Drive Innovation in Consolidated Market

The molecular diagnostics market is highly consolidated, dominated by global molecular diagnostics companies such as F. Hoffmann-La Roche Ltd, Qiagen NV, Thermo Fisher Scientific Inc., and Hologic Inc. These industry leaders maintain their positions through extensive product portfolios and a global reach. The market is characterized by rapid technological advancements, with a strong focus on developing cutting-edge diagnostic solutions for early disease detection, personalized medicine, and point-of-care testing within the molecular diagnostic devices market.

R&D Investment and Strategic Partnerships Fuel Growth

R&D investments play a pivotal role in driving molecular diagnostics market growth. Industry leaders like Thermo Fisher Scientific invest over USD 1.4 billion annually in innovation. Companies are expanding their portfolios through strategic acquisitions and collaborations. For example, Qiagen's 25+ master collaboration agreements with pharmaceutical customers reflect co-development initiatives. Next-generation sequencing and AI-powered diagnostics are also gaining traction, pushing the boundaries of molecular diagnostic technologies.

Emerging Technologies and Market Expansion Drive Future Success

Success in the molecular diagnostics market hinges on embracing emerging technologies and expanding into high-growth markets. Integrating AI and machine learning into diagnostic tools enhances accuracy and efficiency. The development of portable, point-of-care devices within the molecular diagnostic devices market is also rising, driven by the need for accessible diagnostics. Expanding into emerging markets, exemplified by Agilent Technologies' growth strategy, offers new growth opportunities. Multiplex diagnostics, like Sapphiros' molecular multiplex respiratory test, demonstrate the industry's shift towards more comprehensive solutions, aligning with the growing demand for personalized medicine and pharmacogenomics.

Molecular Diagnostics Market Leaders

  1. Hologic Corporation

  2. F Hoffmann-la Roche Ltd

  3. Danaher Corporation (Beckman Coulter Inc.)

  4. Qiagen NV

  5. Thermo Fisher Scientific Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Molecular Diagnostics Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Molecular Diagnostics Market News

  • May 2024: Bruker Corporation completed the acquisition of ELITechGroup a differentiated and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology.
  • January 2024: ELITechGroup launched its in-vitro diagnostic kit, gastrointestinal (GI) Bacterial PLUS ELITe MGB kit, which received the Conformite Europeenne In Vitro Diagnostic Devices Regulation (CE-IVDR) certification. This kit is used to combat bacterial pathogens, including Campylobacter spp., Clostridium difficile, Salmonella spp., and others.

Molecular Diagnostics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Large Outbreaks of Bacterial and Viral Epidemics in the World
    • 4.2.2 Increasing Demand for Point-of-Care Diagnostics
    • 4.2.3 Rapidly Evolving Technologies and Recent Advancements in Pharmacogenomics
  • 4.3 Market Restraints
    • 4.3.1 Limited Budgets for R&D and Economic Slowdown
    • 4.3.2 Need for High-complexity Testing Centers
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Technology
    • 5.1.1 In Situ Hybridization
    • 5.1.2 Chips and Microarrays
    • 5.1.3 Mass Spectrometry (MS)
    • 5.1.4 Sequencing
    • 5.1.5 PCR
    • 5.1.6 Other Technologies
  • 5.2 By Application
    • 5.2.1 Infectious Disease
    • 5.2.2 Oncology
    • 5.2.3 Pharmacogenomics
    • 5.2.4 Microbiology
    • 5.2.5 Genetic Disease Screening
    • 5.2.6 Human Leukocyte Antigen Typing
    • 5.2.7 Blood Screening
  • 5.3 By Product
    • 5.3.1 Instruments
    • 5.3.2 Reagents
    • 5.3.3 Other Products
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Laboratories
    • 5.4.3 Other End Users
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 F Hoffmann-la Roche Ltd
    • 6.1.2 Illumina Inc.
    • 6.1.3 Hologic Inc.
    • 6.1.4 Agilent Technologies Inc.
    • 6.1.5 Qiagen NV
    • 6.1.6 Myriad Genetics Inc.
    • 6.1.7 Becton, Dickinson and Company
    • 6.1.8 Abbott Laboratories
    • 6.1.9 Biomerieux
    • 6.1.10 Bio-Rad Laboratories Inc.
    • 6.1.11 Sysmex Corporation
    • 6.1.12 Danaher Corporation (Beckman Coulter Inc.)
    • 6.1.13 Thermo Fisher Scientific Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Molecular Diagnostics Industry Segmentation

As per the scope of the market report, molecular diagnostic tests detect specific sequences in DNA or RNA (including single nucleotide polymorphisms (SNP), deletions, rearrangements, insertions, and others), which may or may not be associated with diseases. Molecular diagnostics has been revolutionized over the past few decades.

The molecular diagnostics market report is segmented by technology, application, product, end user, and geography. By technology, the market is segmented into in situ hybridization, chips and microarrays, mass spectrometry (MS), sequencing, PCR, and other technologies. By application, the market is segmented into infectious disease, oncology, pharmacogenomics, microbiology, genetic disease screening, human leukocyte antigen typing, and blood screening. By product, the market is segmented into instruments, reagents, and other products. By end user, the market is segmented into hospitals, laboratories, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The industry report also covers the estimated market trends and market share for 17 different countries across major regions globally. For each segment, the market outlook is provided in terms of value (USD). 

By Technology In Situ Hybridization
Chips and Microarrays
Mass Spectrometry (MS)
Sequencing
PCR
Other Technologies
By Application Infectious Disease
Oncology
Pharmacogenomics
Microbiology
Genetic Disease Screening
Human Leukocyte Antigen Typing
Blood Screening
By Product Instruments
Reagents
Other Products
By End User Hospitals
Laboratories
Other End Users
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Molecular Diagnostics Market Research FAQs

What is the market size of molecular diagnostics?

The estimated molecular diagnostics market size for 2025 is a little over USD 14.21 billion. It is forecast to cross USD 22.08 billion by 2030.

What is the future trend in molecular diagnostics?

The future trends in molecular diagnostics include rapid technological advancements, increasing adoption of point-of-care diagnostics, and growing applications in personalized medicine.

What is the outlook for molecular diagnostics?

The outlook for molecular diagnostics is positive, with a projected CAGR of 9.22% from 2025 to 2030. The market is expected to benefit from increasing demand for early disease detection, advancements in genomic medicine, and the development of portable, cost-effective diagnostic devices.

What are the segments of the molecular diagnostics market?

The market is segmented in this report by Technology (PCR, In Situ Hybridization, Chips and Microarrays, Mass Spectrometry, Sequencing, and Others), Application (Infectious Disease, Oncology, Pharmacogenomics, Genetic Disease Screening, Human Leukocyte Antigen Typing, and Others), Product (Instruments, Reagents, and Other Products) and End User (Hospitals, Laboratories, and Other End Users).

What are the applications of molecular diagnostics?

The main applications covered in this report include Infectious Disease (largest segment), Oncology, Pharmacogenomics, Genetic Disease Screening, Human Leukocyte Antigen Typing and Other applications (e.g., drug testing, nephrology, diabetes, autoimmune disorders, and cardiology).

Which area is the biggest player in molecular diagnostics?

North America held the largest share of the molecular diagnostics market, with USD 6,725.54 million in 2025, says Mordor Intelligence. PCR technology commands more than 50% of the global market share.

Molecular Diagnostics Industry Report

This comprehensive report offers a deep dive into the molecular diagnostics industry, providing a detailed analysis of key market drivers and market segments. Mordor Intelligence offers customization based on your specific interests, including: 1. Technology: Isothermal Nucleic Acid amplification Technology( INAAT) 2. Application: Prenatal Tests, Tissue Typing & Cardiovascular Diseases